Multivessel PCI Timing in STEMI
Definition
In patients with STEMI and multivessel coronary artery disease (CAD), complete revascularization refers to treating both the culprit lesion (infarct-related artery) and all angiographically significant nonculprit lesions. The question of timing — whether nonculprit lesions should be treated during the index procedure (immediate) or in a separate procedure after initial stabilization (staged) — has been the subject of several major RCTs. Current evidence, including the MULTISTARS AMI trial, supports that immediate complete revascularization during the index STEMI procedure is at minimum noninferior and potentially superior to a staged approach in hemodynamically stable patients.
Key Concepts
Background: Culprit-Only vs Complete Revascularization (resolved)
- Multivessel CAD is present in approximately 40–50% of STEMI patients and independently increases mortality risk
- Multiple RCTs (PRAMI, CvLPRIT, DANAMI-3-PRIMULTI, COMPLETE) established that complete revascularization is superior to culprit-lesion-only PCI in reducing recurrent MI and ischemia-driven revascularization; the COMPLETE trial additionally showed reduction in cardiovascular death or MI (HR ~0.74) (sources/complete-pci-multistars-ami-nejm-2023, rating: high)
- This question is now considered settled; current ACS guidelines recommend complete revascularization as Class I/A
Immediate vs Staged: MULTISTARS AMI (NEJM 2023) — Primary Evidence
- Design: 840 hemodynamically stable STEMI patients with multivessel CAD; randomized after successful culprit PCI to: (a) immediate multivessel PCI or (b) staged PCI of nonculprit lesions within 19–45 days (sources/complete-pci-multistars-ami-nejm-2023, rating: high)
- Primary outcome: Composite of all-cause death, nonfatal MI, stroke, unplanned ischemia-driven revascularization, or HF hospitalization at 1 year
- Result: Immediate 8.5% vs staged 16.3%; RR 0.52 (95% CI 0.38–0.72); P<0.001 for noninferiority AND superiority (sources/complete-pci-multistars-ami-nejm-2023, rating: high)
- Driver of benefit: Primarily lower nonfatal MI (2.0% vs 5.3%; HR 0.36) and unplanned revascularization (4.1% vs 9.3%; HR 0.42) in the first 45 days; no significant difference in death, stroke, or HF hospitalization
- Landmark analysis: Entire between-group difference occurred in the 0–45-day window (HR 0.33); after day 45, groups converged (HR 0.86, NS)
- Safety: Major bleeding similar (3.1% vs 4.8%; NS); fewer serious adverse events (104 vs 145)
Immediate vs Staged: BIOVASC Trial (Lancet 2023) — ACS Spectrum
- Enrolled patients across the full ACS spectrum (UA, NSTEMI, STEMI) — first RCT to do so
- Showed immediate complete revascularization noninferior to staged strategy across all ACS presentations
- Consistent with MULTISTARS AMI findings, supporting extension of immediate strategy to non-STEMI ACS (sources/complete-pci-multistars-ami-nejm-2023, rating: high)
Mechanistic Rationale for Immediate Strategy
- Nonculprit lesions in STEMI patients frequently exhibit unstable plaque features (thin fibrous cap, large lipid core) on OCT, predisposing to plaque rupture before a staged procedure is performed (COMPLETE OCT substudy data)
- Systemic inflammatory milieu of acute STEMI may destabilize nonculprit plaques
- Achieving complete revascularization immediately reduces the ischemic burden in the vulnerable early post-STEMI period
- Practical advantages: single arterial puncture, reduced contrast volume, reduced radiation, avoidance of a second hospitalization
Key Exclusions (Where Immediate Strategy Has NOT Been Tested)
- Cardiogenic shock: Culprit-only PCI is recommended (CULPRIT-SHOCK trial: multivessel PCI increased 30-day death/renal failure); immediate complete PCI is Class III: Harm
- Left main CAD: Excluded from MULTISTARS AMI — insufficient evidence for immediate complete PCI
- Chronic total occlusion: Excluded — CTO PCI is technically complex; timing in STEMI not established
- Prior CABG: Excluded from MULTISTARS AMI
Guideline Positioning (ACS AHA 2025)
- Complete revascularization in STEMI: Class I/A
- Single-procedure (immediate) multivessel PCI may be preferred over staged: Class IIb/B-R (based on BIOVASC and MULTISTARS AMI) (sources/ACS-AHA-2025 and sources/complete-pci-multistars-ami-nejm-2023, rating: high)
Practical Considerations
- Nonculprit lesion selection should be based on angiographic ≥70% stenosis; FFR guidance is reasonable but was not mandated in the key trials
- Intravascular imaging guidance (IVUS/OCT) was low in MULTISTARS AMI but is increasingly recommended in contemporary practice to optimize stent implantation
- DAPT, statin, and secondary prevention should follow standard post-ACS protocols regardless of revascularization strategy
Contradictions / Open Questions
- Immediate superiority vs guidelines class IIb discordance: MULTISTARS AMI demonstrated p<0.001 superiority for immediate strategy, yet the ACS AHA 2025 guideline only elevated immediate PCI to Class IIb/B-R. This reflects concerns about: (1) open-label design and ascertainment bias for unplanned revascularization; (2) mid-trial endpoint expansion; (3) low female enrollment; (4) single-stent platform (Synergy); (5) consistent with BIOVASC but indirect comparison needed. Further data are expected to potentially upgrade this recommendation. (sources/complete-pci-multistars-ami-nejm-2023, rating: high)
- Optimal staging window: MULTISTARS AMI used a 19–45-day window, which may itself be suboptimal. Whether very early staged PCI (days 3–7) would reduce the pre-staged event risk while avoiding the theoretical risk of immediate PCI in an inflamed milieu is not established.
- FFR/imaging-guided nonculprit PCI: All major trials used primarily visual-assessment criteria. Whether FFR-guided deferral of intermediate lesions (40–70%) would change outcomes is unstudied in the immediate vs staged timing context.
- Long-term equivalence after crossover: After day 45, outcomes were identical — suggesting the immediate benefit is entirely related to preventing events during the waiting period, not a true biological advantage of complete immediate revascularization per se. This raises the question of whether a shorter staging window (e.g., same admission, next day) might achieve similar results.
Connections
- Related to entities/Acute-Coronary-Syndrome — complete revascularization is integral to STEMI management
- Related to concepts/Intracoronary-Imaging-Guided-PCI — imaging guidance during PCI of nonculprit lesions
- Related to concepts/DAPT-Strategies — antithrombotic therapy post-complete revascularization